SEC Comment Letter for BRAINSTORM CELL THERAPEUTICS (BCLI) — May 27, 2026
BRAINSTORM CELL THERAPEUTICS INC.
Date: May 27, 2026 · CIK: 0001137883 · Accession: 0000000000-26-005403
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-296090
Letter
Re: Brainstorm Cell Therapeutics Inc. Registration Statement on Form S-1 Filed May 21, 2026 File No. 333-296090 Dear Chaim Lebovits: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions.
May 27, 2026
Chaim Lebovits Chief Executive Officer Brainstorm Cell Therapeutics Inc. 1325 Avenue of Americas, 28th Floor New York, NY 10019
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Faith Charles, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> May 27, 2026 Chaim Lebovits Chief Executive Officer Brainstorm Cell Therapeutics Inc. 1325 Avenue of Americas, 28th Floor New York, NY 10019 Re: Brainstorm Cell Therapeutics Inc. Registration Statement on Form S-1 Filed May 21, 2026 File No. 333-296090 Dear Chaim Lebovits: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Faith Charles, Esq. </TEXT> </DOCUMENT>